Investors hear a lot about genomics these days, but what does it all mean, exactly? 7investing Lead Advisors Simon Erickson and Maxx Chatsko team up to discuss what investors should look for in pre-commercial drug developers. To provide practical examples, they discuss how continuous improvements in DNA sequencing have created various technological offshoots now loosely called "genomics," including exciting new opportunities in precision oncology and liquid biopsies. Finally, they provide a high-level overview of DNA editing tools and approaches, including base editing and prime editing.


Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year.
Start your journey toward's financial independence: https://www.7investing.com/subscribe
Stop by our website to level-up your investing education:  https://www.7investing.com
Follow us:
► https://www.facebook.com/7investing
► https://twitter.com/7investing
► https://instagram.com/7investing

--- 

Send in a voice message: https://podcasters.spotify.com/pod/show/7investing/message

Gene Editing, Sequencing, Investing — Oh My!

Welcome to 7investing.com. Our mission is to empower you to invest in your future. This podcast brings our market-based experts together to discuss our investing process and important news. Once a month, we will also feature interviews with some of the best minds in business and investing. Check out 7investing.com to find more of our free content and premium monthly stock recommendations.

Business

Investing

Careers

Management & Marketing

Business News

Shopping


If you’ve ever travelled abroad or tried to send money across international borders, hidden fees and unfair exchange rates have no doubt been a massive and expensive headache.
In this week’s episode of the 7investing podcast, Lead Advisors Luke Hallard & Krzysztof Piekarski sit down with Rina Wulfing, Senior Manager for the North American policy team at Wise ($WIZEY) to discuss the company’s original founding story and mission: to empower its users with a transparent system that sends money cost effectively and instantly across borders.


We discuss junk fees — what they are and how Wise is working with regulatory agencies to limit their adverse impact on customers.
We also discuss why direct access to US banking systems is limited to certain types of financial institution, and why this hits US consumers and businesses (and visitors!) in the pocket.If you ever travel internationally, or are looking to upgrade your legacy banking arrangements, today’s episode is a must listen conversation that will give you better insight into the finance industry, and will save you money!



--- 

Send in a voice message: https://podcasters.spotify.com/pod/show/7investing/message

The Hidden Costs of Moving Money: A Wise Perspective

ShockWave Medical (Nasdaq: SWAV), the innovative pioneer of intravascular lithotripsy, has received an all-cash acquisition offer from Johnson & Johnson (NYSE: JNJ) for $335 per share. In today's episode, 7investing advisors Luke Hallard and Simon Erickson discuss why we made ShockWave a 7investing recommendation, several financial details of the offer, and what investors should expect going forward.



--- 

Send in a voice message: https://podcasters.spotify.com/pod/show/7investing/message

Shockwave (SWAV) Receives Buyout Offer from J&J: What Investors Should Know



Investors are continually looking for a good deal in the stock market. But how exactly should we define value?
Quantitatively, publicly-traded companies should serve as compounding machines for their investors. They raise capital -- either through debt or by issuing stock -- then put it to work into projects. If the after-tax profits they generate are greater than their associated costs, they're creating value for us as the owners of the business (i.e. as the investors).
But the investing world is also extremely complex. Markets are changing and being disrupted by new technologies every year. CEOs and leadership teams are continually trying to balance between their desire to be visionary and their need to be efficient. Underinvesting in growth could put a company several steps behind its competitors. Yet going "all-in" on an acquisition that turns out badly could very quickly light their shareholders' capital on fire.
So what are we as the investors to do?
Are there specific metrics we should look at, to determine if a company is using our money responsibly? How should we figure out what the right price is to pay for a stock? And are their any specific stocks out there right now, which might be significantly undervalued and could represent a great bargain for us as investors?




investing CEO Simon Erickson recently spoke with John Rotonti, who is the host of the JRo Show podcast (and available on both Spotify and Apple Podcasts).
John previously worked for nine years at The Motley Fool, where he was an analyst on several newsletters and most recently served as their Head of Investor Training and Development. Simon and John have been friends for a decade, and we recently exclusively published his interview with legendary Fidelity fund manager Joel Tillinghast on our own 7investing site.

Tune in for an in-depth and fascinating look at how to find value in today's stock market.

--- 

Send in a voice message: https://podcasters.spotify.com/pod/show/7investing/message

CROX | AEO | AVGO | INTC | HD | TXN | Searching for Value with John Rotonti

We are on a quest to find the best stock opportunities of the year for investors. Enter for free, with a chance to win a $1,000 Amazon gift card and a free year of 7investing!
To complement our contest, we'll be publishing seven head-to-head matchups between stocks; and we'll include the winners in our own 7investing Team entry.

Our third head-to-head matchup is two companies who are embracing artificial intelligence to make their platforms even better, between The Trade Desk (Nasdaq: TTD) and Palantir Technologies (NYSE: PLTR).
After that, it's the battle of the animals as Crocs (Nasdaq: CROX) takes on American Eagle Outfitters (NYSE: AEO) in a battle for retail dominance! 
Listen to hear the cases for these companies and then head to the 7investing X account to vote for your favorites!

--- 

Send in a voice message: https://podcasters.spotify.com/pod/show/7investing/message

TTD | PLTR | AEO | CROX | Our Best Stocks of 2024 Contest continues!

As part of our Best Stocks of 2024 Contest, we're narrowing down the picks that will be the start of 7investing's entry into our contest! Between now and March 1, 2025, we'll see which stocks will catapult one of our lucky fans to victory, free subscriptions, and a $1000 Amazon gift card. 
Of course, we'll analyze some great companies along way, like Celsius (CELH), Novo Nordisk (NVO), Uber (UBER), and Rocket Lab (RKLB). 
Tune in to hear our breakdowns of these companies and to learn more about how you ca win our Best Stocks of 2024 Contest! 


To enter, go to www.7investing.com/contest/ 



--- 

Send in a voice message: https://podcasters.spotify.com/pod/show/7investing/message

Gene Editing, Sequencing, Investing — Oh My!

Download our free app to listen on your phone